Pfizer Inc (PFE)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 1,043,000 | 1,092,000 | 1,052,000 | 719,000 | 2,853,000 | 3,148,000 | 2,632,000 | 2,166,000 | 416,000 | 1,298,000 | 1,780,000 | 2,470,000 | 1,944,000 | 1,966,000 | 2,372,000 | 1,768,000 | 1,784,000 | 1,587,000 | 1,801,000 | 2,151,000 |
| Short-term investments | US$ in thousands | 19,434,000 | 8,860,000 | 6,049,000 | 11,209,000 | 9,837,000 | 41,033,000 | 42,153,000 | 17,806,000 | 22,316,000 | 34,825,000 | 31,524,000 | 21,427,000 | 29,125,000 | 27,730,000 | 19,328,000 | 11,899,000 | 10,437,000 | 8,912,000 | 9,581,000 | 8,200,000 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 42,995,000 | 43,211,000 | 43,819,000 | 40,497,000 | 47,794,000 | 31,136,000 | 34,647,000 | 36,562,000 | 42,138,000 | 44,314,000 | 47,410,000 | 39,268,000 | 42,671,000 | 41,803,000 | 35,664,000 | 26,652,000 | 25,920,000 | 34,154,000 | 32,723,000 | 33,890,000 |
| Quick ratio | 0.48 | 0.23 | 0.16 | 0.29 | 0.27 | 1.42 | 1.29 | 0.55 | 0.54 | 0.82 | 0.70 | 0.61 | 0.73 | 0.71 | 0.61 | 0.51 | 0.47 | 0.31 | 0.35 | 0.31 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($1,043,000K
+ $19,434,000K
+ $—K)
÷ $42,995,000K
= 0.48
The quick ratio of Pfizer Inc has shown fluctuations over the past few years, indicating changes in the company's liquidity position. The quick ratio measures the company's ability to meet its short-term obligations using its most liquid assets.
From March 2020 to June 2021, the quick ratio gradually increased from 0.31 to 0.61, indicating an improving ability to cover short-term liabilities. This trend suggests that Pfizer's liquidity position was strengthening during this period.
However, in the following quarters up to December 2022, the quick ratio fluctuated, reaching a peak of 0.82 in September 2022 before decreasing to 0.54 by December 2022. These changes may reflect variations in the composition of current assets and liabilities within Pfizer's financial structure.
In the subsequent quarters up to June 2024, the quick ratio continued to fluctuate significantly, ranging from a low of 0.16 in June 2024 to a high of 1.42 in September 2023. These fluctuations suggest ongoing changes in Pfizer's liquidity management and the ability to quickly meet its short-term obligations.
Overall, the quick ratio of Pfizer Inc has exhibited volatility, indicating variations in the company's liquidity position and the need for continuous monitoring to ensure efficient management of short-term financial obligations.
Peer comparison
Dec 31, 2024